Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the appointment of Larry Steenvoorden as Chief Financial Officer effective immediately.
“We are thrilled to welcome Larry to the Chembio executive leadership team. Larry has developed valuable insights over his 25 years of financial leadership experience, spanning accounting, budgeting, public company reporting, business development, and commercial strategy. Those skills will be critical to our success as we scale our business in support of our corporate growth and operational objectives,” said Richard Eberly, Chembio’s President and Chief Executive Officer. “We look forward to working with Larry and are confident his prior roles, particularly as a financial executive at a large publicly traded healthcare conglomerate, make him a perfect fit for Chembio.”
Previously, Mr. Steenvoorden had a 15-year career at Siemens holding roles of increasing responsibility, ultimately as Global Controller & Vice President, Business Planning & Controlling for Siemens Healthcare Diagnostics.
Chembio offers an advanced point-of-care testing platform that delivers multiplexed, accurate, rapid and actionable results that enable healthcare providers to more efficiently manage patients to improve outcomes across decentralized healthcare facilities,” said Mr. Steenvoorden. “As healthcare continues to shift to decentralized settings, Chembio’s tests are well positioned to provide value as this market grows. I am excited to contribute to an organization focused on improving healthcare outcomes for patients worldwide.”